跳到正文
PR Newswire 健康·· 10 天前AI 评分43

Inimmune 在 SITC 2026 公布 INI-4001 最新 Phase 1 结果:晚期实体瘤中显示靶向免疫激活

Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026

AI 导读

Inimmune 公布 INI-4001 的 Phase 1 结果:TLR7/8 小分子激动剂在 10 例重度经治晚期实体瘤患者中未出现剂量限制性毒性,耐受剂量达 7.2 µg/kg,并显示剂量相关细胞因子生成。拟议 Phase 2 剂量下 IFNγ 升高 13.5 倍、IP-10 升高 4.15 倍。2 例患者继续同情用药;公司评估最早 2027 年推进 Phase 2a,但需资金或合作支持。

正文 · 原文

Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagement

Results support continued clinical development of INI-4001 as a potential monotherapy and in combination with other cancer treatments

, /PRNewswire/ -- Inimmune, a clinical-stage biotechnology company developing novel immunotherapies, vaccine adjuvants and other immune-modulating technologies, today announced Phase 1 results for INI-4001, an investigational small-molecule TLR7/8 agonist, in heavily pretreated patients with advanced solid tumors (NCT06302426). The study demonstrated no dose-limiting toxicities (DLTs) and dose-responsive cytokine production consistent with on-target immune activation. The data are being presented today by Shannon Miller, Ph.D., Vice President at Inimmune, in a late-breaking poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

"The Phase 1 data provide encouraging evidence that INI-4001 can activate the TLR7/8 pathway as intended, supporting its potential as a novel approach to cancer immunotherapy," said David Burkhart, Ph.D., Chief Executive Officer of Inimmune. "Despite advances in cancer treatments, many patients do not respond to existing therapies. We believe INI-4001 may help address this challenge by stimulating innate immune activity and making tumors more responsive to immunotherapy. These findings support continued clinical development of INI-4001 as a potential monotherapy, while we also look to explore its use in combination with other cancer treatments."

The Phase 1 study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of INI-4001 in 10 heavily pretreated patients with advanced solid tumors. INI-4001 was administered intravenously once weekly across five escalating dose levels and was tolerated at doses up to 7.2 µg/kg, with no dose-limiting toxicities reported. Adverse events were primarily transient and consistent with innate immune activation, generally resolving within 24 hours. No concerning pharmacokinetic findings were observed.

Pharmacodynamic analyses demonstrated dose-responsive cytokine production consistent with TLR7/8 activation. At the proposed Phase 2 dose, maximum increases from pre-dose levels included 13.5-fold in IFNγ and 4.15-fold in IP-10, supporting evidence of on-target immune activation. Transient, dose-dependent decreases in circulating lymphocytes were also observed, with levels rebounding within 24 hours, consistent with potential lymphocyte trafficking to tissues and tumors.

Although the study was not designed to evaluate efficacy, two of the 10 patients continue to receive INI-4001 under compassionate use, with no reported disease progression. One patient with a small bowel neuroendocrine tumor has received INI-4001 for 19 months, while a second patient with chondrosarcoma has received treatment for nine months.

Based on these findings, Inimmune is evaluating plans to advance INI-4001 into a Phase 2a clinical study as early as 2027 to further assess its potential as a cancer immunotherapy, subject to securing funding or partnership support.

The late-breaking abstract is published in the Journal for ImmunoTherapy of Cancer and can be accessed through the SITC 2026 abstract database.

About INI-4001
INI-4001 is an investigational small-molecule Toll-like receptor (TLR) 7/8 agonist being developed by Inimmune as a potential cancer immunotherapy. Designed to stimulate innate immune responses, INI-4001 is being evaluated for its potential to enhance antitumor immunity. Future development may also explore INI-4001 in combination with existing cancer treatments. INI-4001 has completed a Phase 1 clinical study in patients with advanced solid tumors (NCT06302426).

About Inimmune
Inimmune Corp. is a privately held, clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies, vaccine adjuvants and other immune-modulating technologies. Inimmune is harnessing the human immune system to develop new treatment approaches for cancer, allergy, infectious disease and autoimmunity. The company is based at the Montana Technology Enterprise Center (MonTEC) in Missoula, Montana.

For more information about Inimmune, visit www.inimmune.com.

Contact Information:

Investor Relations
Inimmune Corporation
(406) 541-5913
info@inimmune.com

Media Relations
Sarah Hall
6 Degrees PR
(215) 313-5638
shall@6degreespr.com

SOURCE Inimmune Corporation

来源:PR Newswire 健康 · prnewswire.com